-
Product Insights
Hospital Acquired Pneumonia (HAP) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hospital Acquired Pneumonia (HAP) - Drugs In Development, 2023’, provides an overview of the Hospital Acquired Pneumonia (HAP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Ventilator Associated Pneumonia (VAP) – Drugs In Development, 2023
Global Markets Direct’s, ‘Ventilator Associated Pneumonia (VAP) - Drugs In Development, 2023’, provides an overview of the Ventilator Associated Pneumonia (VAP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Acinetobacter Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Acinetobacter Infections - Drugs In Development, 2023’, provides an overview of the Acinetobacter Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acinetobacter Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Urinary Tract Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Urinary Tract Infections - Drugs In Development, 2023’, provides an overview of the Urinary Tract Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Urinary Tract Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MEMANT-3310 in Acinetobacter Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MEMANT-3310 in Acinetobacter Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MEMANT-3310 in Acinetobacter Infections Drug Details: MEMANT-3310 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MEMANT-3310 in Enterobacteriaceae Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MEMANT-3310 in Enterobacteriaceae Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MEMANT-3310 in Enterobacteriaceae Infections Drug Details: MEMANT-3310 is under development for...
-
Product Insights
Acinetobacter Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acinetobacter Infections – Drugs In Development, 2022, provides an overview of the Acinetobacter Infections (Infectious Disease) pipeline landscape. Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, urinary tract). Symptoms include fever (high body temperature), red, swollen, warm or painful skin areas or wounds. Predisposing factors include weak immune system, poor...
-
Product Insights
Cystic Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis – Drugs In Development, 2022, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape. Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe...
-
Product Insights
Hospital Acquired Pneumonia (HAP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle. The Hospital Acquired Pneumonia Drugs in Development market research report provides an in-depth analysis of the Hospital Acquired Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development...
-
Product Insights
Ventilator Associated Pneumonia (VAP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in the blood). The Ventilator associated Pneumonia Drugs in Development market research report provides an in-depth analysis of the Ventilator associated...